Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

Br J Cancer. 2006 Nov 6;95(9):1142-4. doi: 10.1038/sj.bjc.6603422. Epub 2006 Oct 10.

Abstract

Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0-4.9).

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Carcinoma, Non-Small-Cell Lung / radiotherapy
  • Cisplatin / administration & dosage
  • Clinical Trials, Phase II as Topic
  • Combined Modality Therapy
  • Docetaxel
  • Female
  • Fluorouracil / administration & dosage
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / radiotherapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms, Second Primary / diagnosis*
  • Survival Analysis
  • Survivors*
  • Taxoids / administration & dosage
  • Time Factors

Substances

  • Antineoplastic Agents
  • Taxoids
  • Docetaxel
  • Cisplatin
  • Fluorouracil